27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The PDUFA dates are a key catalyst for any pharma company, especially biotechs, as this is the date when the FDA gives its verdict on the drug’s NDA. The Prescription Drug User Fee Act typically calls for a period of 10 months to review such applications.
March is a month Merck & Co., Inc.(NYSE:MRK) investors were keenly focusing as the company faces key PDUFA catalysts.
Merck’s Keytruda has a PDUFA priority review date on March 8 for Microsatellite Instability-High Cancer and the same drug will have a PDUFA review date on March 15 for Relapsed or Refractory Classical Hodgkin Lymphoma.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is having a PDUFA review date on March 29 for Dupixent (dupilumab) for the treatment of Atopic dermatitis.
In addition, Radius Health Inc (NASDAQ:RDUS)’s PDUFA date for Abaloparatide-SC to treat Osteoporosis is on March 30.
Related Link: 5 Attractive Stocks Trading At A Reasonable PriceRelated Link: 10 Stocks To Watch For March 8, 2017
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!